[Impact of tumor diameter on prognosis in patients with renal cancer stage pT3a.] / Impacto pronóstico del diámetro tumoral en pacientes con cáncer renal estadío pT3a.

OBJECTIVE: To determine the prognostic impact that tumor size has in patients with pathological renal cancer stage pT3a. METHODS: Retrospective, descriptive study evaluating 261 patients diagnosed with renal cancer pathological stage pT1-3aN0M0 between 1995 and 2013. Clinical and pathological characteristics were evaluated in each group. A ROC curve was used to determine the optimum cutting point of tumor size in relation to the death by cancer. Metastasis-free survival and cancer specific survival were evaluated by the Kaplan Meier method and the differences between the groups were evaluated by the Log Rank test. Multivariate Cox regression analysis was used to evaluate the relationship of tumor size and survival of these patients. RESULTS: 261 patients were studied, 166 of which (63.6%) were Stage pT1a-b, 49 (18.8%) pT2 and 46 (17.6%) pT3a. Patients with pT3a tumors had higher proportion of symptomatic tumors (56.5% vs 33.6% p 0.003), tumor size (7.1 cm vs 5.5 cm; 0.0007), Fuhrman grade 3-4 (52.2% vs 19.1% p 0.0001), coagulative necrosis (62.8% vs 28.8% p 0.0001), distance metastasis (39.1% vs 14.9%; p 0.0001) and death by cancer (23.9% vs 8.9%; p 0.003) when compared with localized tumors (pT1-2). The ROC curve demonstrated that a cut-off point of 7cm is the ideal tumor size to determine renal cancer mortality. Metastasis-free survival at 5 year was 90% for tumors pT1a-b, 71% for pT2, 83% for pT3a <7cm and 48% for pT3a >7cm, with significant statistical differences (Log-rank test <0.001). In the multivariate analysis, only pT3a >7cm stage was an independent predictor of death by renal cancer. CONCLUSIONS: Although perirenal fat invasion and renal vein invasion (pT3a stage) are accepted as prognostic factors, to differentiate this category by tumor size could improve its predictive quality. The tumor diameter (7cm) should be applied to pT3a tumors in order to improve the accuracy of TNM system.

[Is CAPRA-S score a valid tool in our environment to predict biochemical recurrence, metastasis and death after radical prostatectomy?] / ?Es el Score CAPRA­S una herramienta válida en nuestro medio para predecir recurrencia bioquímica, metástasis y muerte posterior a prostatectomía radical?

OBJECTIVES: To perform an external validation of CAPRA-S Score to determine prediction of biochemical recurrence, metastasis and death by PCa after RP in Argentinian population. METHODS: 216 patients were studied. The probability of the score to predict biochemical recurrence after RP was analyzed by the Cox proportional method. Biochemical recurrence, metastasis and cancer specific free survivals were determined by Kaplan method. The accuracy of CAPRA-S score to predict biochemical recurrence, metastasis and death by PCa was made in accordance with Harrells concordance index. RESULTS: Median follow up was 74 months. Biochemical recurrence index increased proportionally with the increment of CAPRA-S score. In the stratification of patients in low, intermediate or high risk, biochemical recurrence free rates were 85%, 54% and 4% respectively. Concordance index (C-Index) for biochemical progression, metastasis and death by PCa were 0.85, 0.90 and 0.90 respectively. CONCLUSIONS: CAPRA-S score is an easily applicable tool and has high predictive accuracy to determine biochemical recurrence, metastasis and death by PCa probabilities in our population. Concordance Index in these variables was higher than 0.85.

Hallazgos patológicos y evolución en prostatectomía radical de pacientes candidatos para vigilancia activa / Pathological findings and follow-up of radical prostatectomy patients candidates for active surveillance

El APE ha derivado en el diagnóstico de CaP en etapas más tempranas de la enfermedad. Por otra parte, existen evidencias de que muchos pacientes son sobretratados. La vigilancia activa tiene como premisa reducir el sobre tratamiento y la morbilidad relacionada con el tratamiento primario. El objetivo de este estudio fue evaluar las características patológicas desfavorables en pacientes sometidos a PR que fueron estratificados pre-operatoriamente de bajo riesgo según 10 modalidades para definir pacientes posibles de seguimiento activo. Realizamos un estudio retrospectivo y analítico de 230 pacientes con diagnóstico de CAP y tratados con PR, realizadas entre 1999 y 2011 en el Centro Urológico Profesor Bengió. Se evaluaron las características clínicas en 10 protocolos de seguimiento activo. Las variables anatomopatológicas evaluadas en la pieza de PR fueron el estadio patológico, SG de la pieza operatoria, la extensión extraprostática (EEP), invasión de vesículas seminales y compromiso de ganglios linfíticos regionales. El informe histopatológico fue realizado por un único uropatólogo (VB).En cada uno de los protocolos se evalúa el índice de recurrencia bioquímica. La población del estudio fue 198 pacientes. La media de edad fue 63 años. La media de APE 12,4/ml. Predominaron los estadíos clínicos T1c (48 por ciento) y T2 (48 por ciento). El índice de concordancia entre el SG de la biopsia y la PR en la serie se observó en 128 pacientes (64,6 por ciento). La extensión extraprostática, invasión de vesículas seminales e invasión ganglionar fue encontrada en 44 (22,2 por ciento), 38 (19,2 por ciento) y 3 (1,5 por ciento) pacientes respectivamente. La presencia de elementos patológicos desfavorables en pacientes candidatos a seguimiento activo oscila entre 12 por ciento y el 32 porciento. En nuestra serie de pacientes tratados con prostatectomía radical, los esquemas de vigilancia activa más estrictos, basados en APE <10ng/ml,...

The PSA has resulted in the diagnosis of prostate cancer in earlier stages of the disease. Moreover, there is evidence that many patients are over-treated. Active surveillance tries to prevent overtreatment and reduce the morbidity associated with primary treatment. The aim of this study was to evaluate the adverse pathologic features in patients who underwent RP and were stratified preoperatively as potential candidate for active surveillance through 10 different protocols. A retrospective study of 230 patients diagnosed with CAP treated with PR, conducted between 1999 and 2011 in the Urological Center Professor Bengio. Clinical characteristics were evaluated in 10 active surveillance protocols. Pathologic variables evaluated in RP specimens were pathological stage, surgical specimen SG, extraprostatic extension (EEP), seminal vesicle invasion and regional lymph nodes. The histopathological report was done by a single uropathologist (VB). In each of the protocols biochemical recurrence rate was evaluated. The study population was 198 patients. The average age was 63. The mean PSA 12.4 / ml. Predominant clinical stages T1c (48 percent) and T2 (48 percent). The concordance rate between the SG biopsy and RP in the series was observed in 128 patients (64.6 percent). Extraprostatic extension, seminal vesicle invasion and lymph node involvement was found in 44 (22.2 percent), 38 (19.2 percent) and 3 (1.5 percent) patients, respectively. The presence of unfavorable pathological elements in candidates for active surveillance patients ranges from 12 percent to 32 percent. In our series of patients treated with radical prostatectomy, stricter schemes of active surveillance based on PSA <10ng/ml, clinical stage T1c-T2a, biopsy Gleason score ¡Ü 6 and minimally invasive biopsy (<2 cylinders and <50 percent involvement) show better agreement with favorable histopathology findings in radical prostatectomy and correspond with greater biochemical recurrence-free survival...

Prostate cancer mortality trends in Argentina 1986-2006: an age-period-cohort and joinpoint analysis.

The aim of this study was to give an overview of the magnitude, variation by age and time trends in the rates of prostate cancer mortality in Córdoba province and in Argentina as a whole from 1986 to 2006. Mortality data were provided by the Córdoba Ministry of Health and the World Health Organization cancer mortality database. Prostate cancer mortality time trends were analyzed using joinpoint analysis and age-period-cohort models. In Argentina prostate cancer age-standardized mortality rates rose by 1% and 3.4% per year from 1986 to 1992 and from 1992 to 1998 respectively. There was a decreasing trend (-1.6%) for Argentina from 1998 and Córdoba (-1.9%) from 1995. Age-period-cohort models for the country and the province showed a strong age effect. In the country there was an increased risk in the 1996-2000 period, whereas there was decreased risk for birth cohorts since 1946, principally in Córdoba. A decreasing trend in prostate cancer mortality was found in Córdoba as well as in Argentina, which might be attributed to the improvement in treatment in this country.

Prostate cancer mortality trends in Argentina 1986-2006: an age-period-cohort and joinpoint analysis / Tendencias en la mortalidad por cáncer de próstata en Argentina 1986-2006: análisis joinpoint y de edad-período-cohorte

The aim of this study was to give an overview of the magnitude, variation by age and time trends in the rates of prostate cancer mortality in Córdoba province and in Argentina as a whole from 1986 to 2006. Mortality data were provided by the Córdoba Ministry of Health and the World Health Organization cancer mortality database. Prostate cancer mortality time trends were analyzed using joinpoint analysis and age-period-cohort models. In Argentina prostate cancer age-standardized mortality rates rose by 1 percent and 3.4 percent per year from 1986 to 1992 and from 1992 to 1998 respectively. There was a decreasing trend (-1.6 percent) for Argentina from 1998 and Córdoba (-1.9 percent) from 1995. Age-period-cohort models for the country and the province showed a strong age effect. In the country there was an increased risk in the 1996-2000 period, whereas there was decreased risk for birth cohorts since 1946, principally in Córdoba. A decreasing trend in prostate cancer mortality was found in Córdoba as well as in Argentina, which might be attributed to the improvement in treatment in this country.

El objetivo de este trabajo fue describir la magnitud, la variación por edad y las tendencias temporales de las tasas de mortalidad por cáncer de próstata en la provincia de Córdoba y en Argentina desde 1986 hasta 2006. Se ajustaron modelos joinpoint y de edad-período-cohorte con los datos de mortalidad del Ministerio de Salud de Córdoba y de la Organización Mundial de la Salud. En Argentina las tasas de mortalidad estandarizada por edad aumentaron 1 por ciento y 3,4 por ciento por año desde 1986 a 1992 y desde 1992 a 1998 respectivamente. Fue estimada una tendencia decreciente (-1.6 por ciento) para Argentina desde 1998 y para Córdoba (-1.9 por ciento) desde 1995. Los modelos edad-período-cohorte tanto para Córdoba, como para el país, mostraron un marcado efecto de edad. En el país se encontró un incremento del riesgo en el período 1996-2000, mientras que las cohortes de nacimiento a partir de 1946 mostraron un riesgo decreciente, principalmente para Córdoba. Se encontró una disminución en las tasas de mortalidad por cáncer de próstata en Córdoba y en Argentina, lo cual podría atribuirse a mejoras en los tratamientos en el país.

Implantes intersticiales con Au198 en cancer prostatico / Interstitial implant with Au198 in prostatic cancer

Desde el año 1983 hasta 1987 fueron tratados 13 pacientes con cáncer de próstata cuya edad promedio fue 64.5 años agrupados de acuerdo a la clasificación de Whitmore y Jewett, incluyéndose en este estudio a los enfermos con estadios clínicos B1, B2, C1, y C2. A todos los pacientes se les practicó linfadenectomía ilioobturatriz bilateral con fines diagnósticos; en el mismo acto quirúrgico se efectuó el implante intersticial con semillas de oro radioactivo (Au198). Las dosis de irradiación administrada a la próstata fue de 40 Gy desde el implante intesticial complementado con radioterapia externa (CO60) hata 60 Gy equivalentes. En los casos donde la linfadenectomía resultó positiva se extendieron los campos de irradiación para incluir las cadenas ganglionares pelvianas. El resultado obtendo por este tratamiento fue para los 13 pacientes la reducción del tamaño prostático con normalización de la micción y de los exámenes complementarios. De los 13 pacientes, 3 presentaron metástasis óseas durante el seguimiento, uno de los cuales se acompaño también de recidiva local. Las complicaciones por la radioterapia fueron leves o moderadas. Sólo un pacientes fue sometido a colostomía por rectitis actínica severa, pero el mismo sufría de enfermedad rectal previa. Los resultados obtenidos hasta el cierre de este primer informe pueden consdierarse satisfactorios si es toman en cuenta la respuesta tumoral y el control local de la enfermedad, pero el tiempo promdeio de seguimiento es corto apra evaluar la sobrevida